HumanZyme and Pacific GMP Form Cell Therapy Partnership

HumanZymeandPacificGMPenteredintoapartnershiptomanufactureclinicalgradehumangrowthfactorsandcytokines.Thegoalistoprovideasourceoftheseproteinstoregenerativemedicinedeveloperstochangestemcellsintodifferentiatedcelltypesthatwillbeusedtotreatvariousdiseasesorinjuries.
HumanZymebringsitsHumanKinegrowthfactorandcytokineproductlinetothepartnershipwithPacificGMP,whichhasexperienceinmanufacturingGMP-certifiedrecombinanthumanproteinsintendedforhumanclinicaluse.
"PacificGMPhasastate-of-the-artmanufacturingfacilityandaverysuccessfultrackrecordofmanufacturingclinicalgradeproteinsinthelargequantitiesthatareneededtosupportthedemandgeneratedbyanapprovedtherapy,"saidScottColeridge,CEOofHumanZyme."WearemakingourproprietarytechnologyavailabletoPacificGMPtoenabletheproductionofourHumanKinegrowthfactorsandcytokineswhichwillhelpallowregenerativemedicinecompaniestoadvancedevelopmentofstemcelltherapies."
"HumanZyme’sproductioncelllinesandcultureconditionshavethenecessaryfeaturesforeasyadaptiontoaGMPenvironment,"addedGaryPierce,CEOofPacificGMP."Inaddition,thehumancells,theserum-freecellculture,andacompletelyanimalcomponent-freeprocesswillhelpensurethatthemanufacturedproteinsarebothbioactiveandsafe.”
AMedMarketDiligencereportestimatesthatthetissueengineeringandcelltherapymarketcurrentlytotals$12billiononaglobalbasis.Thereportspredictsthatthisnumberwillincreaseto$32billionby2018.